Principal Scientist:

Dr. Vinod Chaudhari



Contact Address

Medicinal Chemistry Lab,
3rd Floor, Main Building


Medicinal Chemistry, Drug discovery, Synthetic Organic Chemistry, Carbohydrate Chemistry.


Dr. Vinod Chaudhari is a Medicinal Chemist, received his PhD in Synthetic Organic/Carbohydrate Chemistry from University of Pune, Pune and subsequently moved to University Joseph Furrier (CNRS), Grenoble, France for a Post-Doctoral training on Synthetic Organic Chemistry. He has over 12 years of Synthetic and Medicinal Chemistry research experience in Indian Industries. He has worked at Lupin Research Park Pune, Aurigene Discovery Technology Ltdand Zydus Research Centre, prior to joining CSIR-IMTECH Jan 2019. Vinod has experience in leading drug discovery teams that successfully delivered several preclinical/clinical development candidates. He has experience in working with various target classes including GPCRs, Ion channels and Kinases, across different therapeutic areas like Metabolic disorders, Oncology, Respiratory diseases, Inflammation, and Neurosciences. At CSIR-IMTECH his research group focus will be on new drug discovery in the different therapeutic areas like of Antimicrobial resistance, Infectious and Neglected diseases. Currently working on design and synthesis of novel small molecules targeting different targets for the therapeutic area of Respiratory infectious diseases particularly tuberculosis (TB) andAntimicrobial resistance (AMR).His research focus will be also on total synthesis of biologically active natural/unnatural products using chiral template derived from carbohydrate.

Selected Patents

  • Arylalkylamine Compounds as Calcium Sensing Receptor Modulators. WO2014/033604, US2015/239827, US2016/075655, US2017/0137371, EP2888225, AU2013/308081, CA2882039, CN104583177, IN421MUN2015, JP2015/528462, HK1211916.
  • Substituted Morpholines as Modulators for The Calcium Sensing Receptor. WO2012/120476, US2013/345213, US2016/0250219, EP2683697, AU2012/226375, CA2828415, ZA2013/06576, IN2011KOL31720110310.
  • Diaza-spiro[5,5]undecanes as Orexin Receptor Antagonists; WO2011/076747, US2012/2264748, EP2516439, JP2013/515033, AR079553, CN102762567, TW2011/32642, UY33125; Novartis AG, Switzerland.
  • Disubstituted Heteroaryl-Fused Pyridines.WO2011/076744, US2012/258973, EP251637, CN102762560, IN2009/02664, JP2013/515032.
  • Di/tri-Aza-Spiro-C9-C11 Alkanes. WO2012/101487, US2012/165331, AR084430.

Major Publications

  • Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models. Shukla, M. R., et. al.; Journal of Medicinal Chemistry, 2020, 63 (23), 14700–14723.
  • Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics? Bajeli, S., et. al., Front. Cell. Infect. Microbiol., 2020, 10: 589348.
  • Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs). Behnke,D.,et. al.;Bioorganic & Medicinal Chemistry Letters, 2015, 25 (23), 5555–5560.
  • Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia. BetschartC., et al; Journal of Medicinal Chemistry, 2013, 56 (19), 7590–7607.
  • An Efficient Synthesis of D-erythro- and D-threo-Sphingosine from D-Glucose: Olefin Cross-Metathesis Approach. Chaudhari, V. D., et. al.; Organic Letters,2005, 7, 5805-5807.

For Complete Profile: Click Here